Cargando…

Hydroxychloroquine: risk of QT prolongation and drug interactions

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	News Item
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453867/ http://dx.doi.org/10.1007/s40278-020-82544-1

Ejemplares similares

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

PRAC review confirms chloroquine- and hydroxychloroquine-related AEs
Publicado: (2020)

Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
Publicado: (2020)

Hydroxychloroquine-associated QT interval prolongation
Publicado: (2020)

Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
por: Choi, Byung Jin, et al.
Publicado: (2021)

An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation
por: Yetkin, E., et al.
Publicado: (2020)

QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020)

COVID-19 pregnancy prevention guidance on teratogenic drugs
Publicado: (2020)

New potential interaction with emergency COVID-19 medicine remdesivir
Publicado: (2020)

ISMP issues safety warnings for drug shortage replacement products
Publicado: (2020)

Health Canada approves first drug for treatment of COVID-19
Publicado: (2020)

FDA remote evaluation of drug manufacturing during COVID-19
Publicado: (2021)

Revisions of precautions for COVID-19 vaccines and other drugs in Japan
Publicado: (2021)

Hydroxychloroquine and QT prolongation: reassuring data in approved indications
por: Pareek, Anil, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report
Publicado: (2020)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

COVID-19 vaccination and risk of neuralgic amyotrophy
Publicado: (2022)

Tozinameran vaccination in Canada: no change in benefit-risk profile
Publicado: (2021)

Warnings of risks associated with ivermectin use for COVID-19
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

PRAC updates risk of myocarditis and pericarditis with mRNA vaccines
Publicado: (2021)

Merck says molnupiravir has favourable benefit-risk assessment
Publicado: (2021)

EMA guidance on risk management plans for COVID-19 vaccines reviewed
Publicado: (2020)

No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
Publicado: (2021)

Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
Publicado: (2021)

AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
Publicado: (2021)

Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits
Publicado: (2022)

Azithromycin/hydroxychloroquine interaction: QT interval prolongation following off-label use: case report
Publicado: (2020)

Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
por: O’Connell, Thomas F., et al.
Publicado: (2021)

Hydroxychloroquine: QT prolongation due to off-label use: case report
Publicado: (2022)

HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)

Remdesivir-related acute kidney injury in patients with COVID-19
Publicado: (2020)

EMA's CHMP meeting highlights from September 2020
Publicado: (2020)

UK's MHRA publishes guidance for valproate PPP during pandemic
Publicado: (2020)

TGA advises of potential taste disturbance with Andrographis paniculata
Publicado: (2020)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

Women disadvantaged by employment-based health financing
Publicado: (2020)

Codeine-containing medicines to be reclassified in NZ
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Concerns raised with MHRA of anticoagulant use during pandemic
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9bhdueqptk2ua14msnbtnhsio